Transplantation, Liver Clinical Trial
Official title:
Pharmacokinetics of Intravenous / Oral MMF and Oral Tacrolimus in Live Donor and Deceased Donor Liver Transplant Patients
The purpose of this study is to measure the amount of MMF and tacrolimus concentration in the blood at a given time. Currently MMF is ordered as a set dose and tacrolimus is given based on body weight. While the deceased donor transplant receives the complete liver, in the live donor just over half of the liver is given (about 60%). The way these different types of transplants break down drugs could be different. Measuring the drug levels allows us to know what happens to the medication in between the morning and the evening dose.
The purpose of this study is to measure the amount of MMF and tacrolimus concentration in
the blood at a given time. Currently MMF is ordered as a set dose and tacrolimus is given
based on body weight. While the deceased donor transplant receives the complete liver, in
the live donor just over half of the liver is given (about 60%). The way these different
types of transplants break down drugs could be different. Measuring the drug levels allows
us to know what happens to the medication in between the morning and the evening dose.
12 subjects with live liver donors and 12 subjects with deceased donors will be included in
the study.
Each patient will have 12 (twelve) blood samples (half a teaspoon) drawn at 0,1, 2, 3, 4,
4½; 5, 6, 7, 8, 10 and 12 hours from an intravenous line placed during the operation. At the
same time, 24-hour urine will be collected to measure your kidney function. After 4 to 6
days post transplant when the will be switched to oral MMF, again 10 (ten) blood samples a
half teaspoon each will be drawn at 0, 1, 2, 3, 4, 5, 6, 8, 10, 12 hours. Blood will be
drawn with the routine daily blood work for the first 14 days and then at 1 and 3 months
after transplant. Total blood drawn over 3 months will be about 7 tablespoons. A 24-hour
urine will be collected in a container given to you starting one day before the routine
clinic visit (as a standard of care). The 24-hour urine will be collected at 1 and 3 months
after transplant as well.
If a woman, who could become pregnant, a pregnancy test will be done before your transplant.
They would also have to use birth control during the study period and 6 months after the
completion of study.
;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02498977 -
Liver Immunosuppression Free Trial
|
Phase 4 | |
Completed |
NCT00166556 -
A Trial to Assess Campath-1H and Tacrolimus Followed by Immunosuppression Withdrawal in Liver Transplantation
|
Phase 2 | |
Terminated |
NCT02356939 -
Removable Intraductal Stenting in Duct-to-duct Biliary Reconstruction in Liver Transplantation
|
N/A | |
Completed |
NCT00117689 -
Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection
|
Phase 2 |